[HTML][HTML] The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours
The fifth edition of the World Health Organization (WHO) classification of urogenital tumours
(WHO “Blue Book”), published in 2022, contains significant revisions. This review …
(WHO “Blue Book”), published in 2022, contains significant revisions. This review …
Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
Abstract The Genitourinary Pathology Society (GUPS) undertook a critical review of the
recent advances in renal neoplasia, particularly focusing on the newly accumulated …
recent advances in renal neoplasia, particularly focusing on the newly accumulated …
Radiogenomics in renal cancer management—current evidence and future prospects
M Ferro, G Musi, M Marchioni, M Maggi… - International journal of …, 2023 - mdpi.com
Renal cancer management is challenging from diagnosis to treatment and follow-up. In
cases of small renal masses and cystic lesions the differential diagnosis of benign or …
cases of small renal masses and cystic lesions the differential diagnosis of benign or …
WHO 2022 landscape of papillary and chromophobe renal cell carcinoma
The 5th edition of the WHO Classification of Tumours of the Urinary and Male Genital
Systems contains relevant revisions and introduces a group of molecularly defined renal …
Systems contains relevant revisions and introduces a group of molecularly defined renal …
The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges
SK Mohanty, A Lobo, L Cheng - Human pathology, 2023 - Elsevier
The fifth edition of the World Health Organization (WHO) classification of urinary and male
genital organ tumors has been recently published in 2022. The application of molecular …
genital organ tumors has been recently published in 2022. The application of molecular …
Papillary renal cell carcinoma: current and controversial issues
S Angori, J Lobo, H Moch - Current opinion in urology, 2022 - journals.lww.com
Papillary renal cell carcinoma: current and controversial is... : Current Opinion in Urology
Papillary renal cell carcinoma: current and controversial issues : Current Opinion in Urology …
Papillary renal cell carcinoma: current and controversial issues : Current Opinion in Urology …
The morphological spectrum of papillary renal cell carcinoma and prevalence of provisional/emerging renal tumor entities with papillary growth
Renal cell carcinoma (RCC) represents a heterogeneous disease, encompassing an
increasing number of tumor subtypes. Post-2016, the World Health Organization (WHO) …
increasing number of tumor subtypes. Post-2016, the World Health Organization (WHO) …
“Oncocytoid Renal Cell Carcinomas After Neuroblastoma” Represent TSC-mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas: Association With Prior …
The concept of oncocytoid renal cell carcinoma in patients who have survived
neuroblastoma as a distinct biologic entity has been controversial since its original …
neuroblastoma as a distinct biologic entity has been controversial since its original …
A novel NIPBL-NACC1 gene fusion is characteristic of the cholangioblastic variant of intrahepatic cholangiocarcinoma
We report a novel NIPBL-NACC1 gene fusion in a rare primary hepatic neoplasm previously
described as the “cholangioblastic variant of intrahepatic cholangiocarcinoma.” The 2 index …
described as the “cholangioblastic variant of intrahepatic cholangiocarcinoma.” The 2 index …
[HTML][HTML] Emerging role of Hippo-yap (yes-associated Protein)/TAZ (transcriptional coactivator with PDZ-Binding motif) pathway dysregulation in renal cell carcinoma …
V Mondal, PJ Higgins, R Samarakoon - Cancers, 2024 - mdpi.com
Simple Summary The mechanisms of renal cell carcinoma (RCC) progression are not well
understood. There is a need to develop effective therapies against metastatic disease and to …
understood. There is a need to develop effective therapies against metastatic disease and to …